Confo Therapeutics

Confo Therapeutics discovers novel medicines targeting G-protein coupled receptors (GPCRs), focusing on Class B GPCRs for the treatment of chronic endocrine and metabolic diseases. Their proprietary platform, including ConfoBody® and ConfoChimer® technologies, enables the discovery of molecules targeting challenging GPCRs. The company is advancing a pipeline of large and small molecules.

Buy Funded Startups lists

Funding Round: Grant

Funding Amount: €1.6M

Date: 28-Mar-2024

Investors: VLAIO

Markets: Pharmaceuticals, Biotechnology, Drug Discovery

HQ: Ghent, Flanders, Belgium

Founded: 2015

Website: https://www.confotherapeutics.com/

LinkedIn: https://be.linkedin.com/company/confo-therapeutics

Twitter:

Instagram: